Anti-erythropoietin antibodies
The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.
1. An isolated antibody or fragment of an antibody, wherein the antibody or the fragment specifically binds to human erythropoietin and comprises:
a. a variable heavy chain complementarity determining region 1 (VH CDR1) having the amino acid sequence SEQ ID NO: 36;
b. a variable heavy chain complementarity determining region 2 (VH CDR2) having the amino acid sequence SEQ ID NO: 37;
c. a variable heavy chain complementarity determining region 3 (VH CDR3) having the amino acid sequence SEQ ID NO: 38;
d. a variable light chain complementarity determining region 1 (VL CDR1) having the amino acid sequence SEQ ID NO: 6;
e. a variable light chain complementarity determining region 2 (VL CDR2) having the amino acid sequence SEQ ID NO: 7; and
f. a variable light chain complementarity determining region 3 (VL CDR3) having the amino acid sequence SEQ ID NO: 8.
2. An isolated antibody or antibody fragment, wherein the antibody or the fragment specifically binds human erythropoietin and comprises: a heavy chain variable domain comprising the amino acid of SEQ ID NO: 75; and comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 67.
3. The antibody of claims 1 or 2 , wherein the antibody is a monoclonal antibody.
4. The antibody of claim 3 , wherein the antibody is a chimeric antibody, a humanized antibody, or a fully human antibody.
5. A sterile composition comprising the isolated antibody or antibody fragment of any one of claims 1 or 2 .
6. A kit for detecting antibody-mediated pure red cell aplasia (amPRCA) or predicting the risk or onset of AMPRC comprising the anti-human erythropoietin antibody of claims 1 or 2 , and human erythropoietin.